TuHURA Biosciences, Inc.(HURA)

Biotechnology · Tampa, FL

$1.89+0.02 (+0.97%)

Delayed quote: Oct 6, 2026, 10:25 AM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T14:26:47.427Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:26:47.427Z.

Quote observation: 2026-10-06T14:25:07.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 120,238,928
Total debt · period ending 2026-06-30: 407,023
Cash · period ending 2026-06-30: 995,977
TTM operating EBITDA · period ending 2026-06-30: -31,100,731

FMP input reference: 521b0ab3da901f2a49dafbbedcb3688a082548b97bbb2cd5efdb729e6989e7c5

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

HURA EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

HURA Competitors' EV/EBITDA Ratio

HURA

TuHURA Biosciences, Inc.

Current

Market Cap

$120.24M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ENGN

enGene Holdings Inc.

vs HURA

Market Cap

$121.25M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LENZ

LENZ Therapeutics, Inc.

vs HURA

Market Cap

$116.83M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CBUS

Cibus, Inc.

vs HURA

Market Cap

$123.66M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IMDX

Insight Molecular Diagnostics Inc.

vs HURA

Market Cap

$116.57M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CRBU

Caribou Biosciences, Inc.

vs HURA

Market Cap

$116.54M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ENTX

Entera Bio Ltd.

vs HURA

Market Cap

$124.95M

EV/EBITDA Ratio

N/A

TTM Avg

3.93x

3Y Avg

3.93x

5Y Avg

3.93x

GNLX

Genelux Corporation

vs HURA

Market Cap

$114.79M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MXCT

MaxCyte, Inc.

vs HURA

Market Cap

$114.62M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LUCD

Lucid Diagnostics Inc.

vs HURA

Market Cap

$112.52M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
TuHURA Biosciences, Inc. (HURA)	$120.24M	N/A	N/A	N/A	N/A
enGene Holdings Inc. (ENGN)vs ›	$121.25M	N/A	N/A	N/A	N/A
LENZ Therapeutics, Inc. (LENZ)vs ›	$116.83M	N/A	N/A	N/A	N/A
Cibus, Inc. (CBUS)vs ›	$123.66M	N/A	N/A	N/A	N/A
Insight Molecular Diagnostics Inc. (IMDX)vs ›	$116.57M	N/A	N/A	N/A	N/A
Caribou Biosciences, Inc. (CRBU)vs ›	$116.54M	N/A	N/A	N/A	N/A
Entera Bio Ltd. (ENTX)vs ›	$124.95M	N/A	3.93x	3.93x	3.93x
Genelux Corporation (GNLX)vs ›	$114.79M	N/A	N/A	N/A	N/A
MaxCyte, Inc. (MXCT)vs ›	$114.62M	N/A	N/A	N/A	N/A
Lucid Diagnostics Inc. (LUCD)vs ›	$112.52M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics